Treatment of cancer by activation of an antitumor immune response is now a widely practiced and well-accepted approach to therapy. However, despite dramatic responses in some patients, the high proportion of unresponsive patients points to a considerable unmet medical need. Although antibody therapies have led the way, small molecule immuno-oncology agents are close behind. This perspective provides an overview of some of the many small molecule approaches being explored. It encompasses small molecule modulators of validated targets such as programed cell death 1 (PD-1) as well as novel approaches still to be proven clinically.
Keywords: ARAQTZDRSNRIIK-UHFFFAOYSA-N; BEDXOYXWXUCQNA-IPJVBHEBSA-N; Cancer; FAVUUGQWYAJEGA-UHFFFAOYSA-N; FVWQPAOQPHOQRR-UHFFFAOYSA-N; HUVQZTCJKOXROE-RPXLBNRVSA-N; HWDKOBHGPXRKJJ-HMZIZCGUSA-J; Immuno-oncology; JWVAXOHLLDJSHF-QMJXVMRNSA-N; KRESAFFTFXNKOO-UHFFFAOYSA-N; MFZUODXFGTXTIW-GBEGKXJTSA-N; NINCPJHFIWWUAZ-CDRJQVBSSA-N; RBFLMTFTTMGEPS-UHFFFAOYSA-N; Small molecule; UATCGUSLBHISQR-ALSSIMQBSA-N; UBQQSDUBSSXCEW-DZHBTMGUSA-N; VDNKHSAOWUDCRM-ACSVFZNHSA-N; WUDIWKVIWHAQIO-UHFFFAOYSA-N.
Copyright © 2017 Elsevier Ltd. All rights reserved.